Introduction
============

Globally colon cancer (CC) has the third highest rate of malignancy, which is associated with a high rate of mortality. In over one-third of patients with CC will evolve into metastatic disease with a five-year survival rate of only \~ 10% [@B1]. Chemotherapy using the third generation platinum drug oxaliplatin (OXA) improves overall survival (OS) for advanced or metastatic CC patients [@B2]. Unfortunately, OXA-resistance is still a major factor in the poor prognosis associated with advanced CC. Despite numerous attempts to understand the mechanism(s) of OXA-resistance, which have focused on drug effluxes, drug target mutation, DNA damage repair and the cell death escape. OXA-sensitivity has not been effectively improved yet in colon cancer [@B3].

We have evidence indicating that epithelial mesenchymal transition (EMT) is closely involved in chemo-resistance. Malignant cells undergoing EMT acquire migration and drug resistance characteristics [@B4], [@B5]. Stimulating EMT by up-regulating Nestin expression enhances chemo-resistance in hepatocellular cancer [@B6]. Most importantly, we recently found that EMT regulates cell invasion and OXA-sensitivity *via* the Snail pathway in hepatocellular cancer cells [@B7]. EMT is a process characterized by: (i) the absence of polarity and intercellular adhesion of epithelial cells, and (ii) the acquisition of mesenchyme features associated with higher motility, and (iii) the altered expression of EMT biomarkers (down-regulation of epithelial marker E-cadherin, and up-regulation of the mesenchymal marker Vimentin) [@B8], [@B9]. EMT is also associated with cancer stemness properties, including self‑renewing and multi-directional differentiation potential, which promotes drug resistance [@B10], [@B11]. The degradation of extracellular matrix (ECM) by secretory enzymes is evidence of EMT progression; Degradation of ECM promotes cell expansion and cell mobility in a matrix metalloproteinase (MMP) dependent manner [@B12].

A set of transcriptional factors are reportedly involved in the occurrence of EMT [@B9], [@B13]. For example, Snail, ZEB, Twist and Slug transcription factor families may be important modulators of EMT, through direct binding of the E-box region of E-cadherin promoter, resulting in repression of E-cadherin transcription [@B14], [@B15]. ZEB1 reportedly participates in embryonic formation and cell differentiation. Recent studies suggest that ZEB1 is involved in triggering the occurrence of EMT and is associated with poor prognosis in cases of human carcinoma [@B16], [@B17]. However, the role(s) of ZEB1 in EMT regulation and OXA-resistance remain to be elucidated.

The aim of this study is to investigate the role(s) of ZEB1 in OXA-resistance related to EMT in colon cancer, which may reveal novel strategies for defeating OXA-resistance.

Materials and Methods
=====================

Chemicals and drugs
-------------------

OXA was purchased from Selleck Chemicals (Huston, TX) and was diluted with DMSO (Sigma, St Louis, MO) and stored at the concentration of 10 mM. The primary antibodie against ZEB1 was purchased from Sigma. The primary antibodies against E-cadherin, Vimentin, Snail and Slug were purchased from Cell Signaling Technology (CST, Danvers, MA). The primary antibodies against Twist, MMP2, MMP9, Caspase-3 and Bcl-2 were purchased from Abcam (Cambridge, MA, UK).

Patients and follow-up
----------------------

A total of 118 pairs of colon tumor tissues and adjacent non-tumorous tissues (paraffin-embedded tissues) were randomly collected from advanced stage IV colon cancer patients between January 2009 and March 2015 in Human Important Disease Specimen Bank of Xiangya Hospital (Central South University, Changsha, Hunan, China). Among which, those paired sample were collected by enteroscopy biopsy or exploratory laparotomy biopsy. And those patients were received OXA-based (FOLFOX) chemotherapy regimens for six months at minimum after diagnosed. FOLFOX4 regimen : (OXA 85 mg/m^2^ i.v. on day 1; LV 200 mg/m^2^ i.v. 2 hours on days 1 and 2; and FU 400 mg/m^2^ i.v. bolus at hour 2, then 600 mg/m^2^ over 22 hours on days 1 and 2, once every 2 weeks).

The study complied with the Declaration of Helsinki and approved by the Ethics Committees of Xiangya hospital. Clinical follow-up data were obtained from the patients through telephone inquiry and outpatient clinic visit. Follow-up was terminated on September 2016. The follow-up period was defined as the interval between the date of diagnosis and that of the patient\'s death or the last follow-up. Follow-up time ranged from 1 to 18 months. The data of deaths from other causes and the surviving patients at the last follow-up were all censored. OS was defined as the time quantum from diagnosis to death or status on the last inquiry, while progression-free survival (PFS) was defined as the time interval between the first time of chemotherapy and the first evidence of recurrence.

Cell culture
------------

The human normal epithelial colon cell line NCM460 was purchased from Xiangya cell bank (Central South University, Changsha, China). The human colon cancer cell line HCT116 was obtained from the Institutes of Biomedical Sciences (IBS, Shanghai, China), and HCT116/OXA cells with OXA resistance were purchased from the corporation of MEIXUAN Biological Science & Technology (Shanghai, China). Cells were cultured in 25-cm^2^ flasks in RPMI-1640 (Gibico, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin sodium and 100 μg/mL streptomycin sulfate (Hyclone, Logan, UT) at 37 °C in a 5% CO~2~ atmosphere.

Chemo-sensitivity**assay**
--------------------------

Chemo-sensitivity was measured using Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Tokyo, Japan). The cells were seeded at a concentration of 1.0 × 10^4^ cells/well in a 96-well plate and grown in RPMI-1640. 24 hrs later, OXA was added to the culture medium at ten different final concentrations: 0, 1.25, 2.5, 5, 10, 20, 40, 80, 160 and 320 μM. After 48 hours of OXA treatment, 10 μl of CCK8 reagent was added per well and the plate was incubated at 37℃ for 1 h. We measured OD values for each well (wavelength: 450 nm). All assays were performed in triplicate.

Colony formation assays
-----------------------

To identify the proliferation of colon cancer cells**,** HCT116 and HCT116/OXA cells were seeded in 6-well plates at a density of 1 × 10^3^ cells/ well and cultured in standard culture media without OXA treatment. The media was replaced every 3 days. After being incubated for two weeks, the cells were fixed with paraformaldehyde and then stained with 0.1% crystal-violet for 20 minutes at room temperature; cell colonies with \> 50 cells were counted.

Invasion and migration assays
-----------------------------

Invasion chambers (BD Biosciences, San Jose, CA) were used to determine the invasiveness of colon cancer cells. The cells were harvested after 12 hours in serum-free medium. At a density of 5 × 10^3^ cells/well, cells were transferred to the matrigel chambers along with 200μl of serum-free medium in the upper chamber and 600μl of standard medium in the bottom chamber. After 48 hours incubation, the cells in the upper chamber were discarded, and the invaded cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet for 20 mins. The images were captured using a Leica DMI-4000B inverted microscope (Leica, Wetzlar, Germany) and the number of invaded cells was counted.

The scratch wound-healing assay was performed to detect the migration abilities of colon cancer cells. The cells were seeded into 6-well plates, and scratches were made using a 200-μl pipette tip. Floating cells were discarded. Cells were cultured continuously for 48 hrs. Cell images were captured using an inverted microscope (Leica DMI-4000B), and migration distances were calculated using LAS V4.0 software (Leica).

Flow cytometry
--------------

Cells were treated with or without OXA for 48 hrs and then stained with Annexin V-FITC and propidium iodide (PI) according to the manufactures\' instructions (BD Biosciences). A FACS Canto II flow cytometer (BD Biosciences) was used to measure apoptosis rate.

RNA interference
----------------

Three candidate small interfering RNA (SiRNA) targeting human ZEB1 (GenBank Accession NO.: NC_000010.11) were chemically synthesized by Sangon Biotech (Shanghai, China). The SiRNA oligonucleotide sequences are as follows: SiRNA1: sense 5′-CCUAGUCAGCCACCUUUAATT-3′; antisense 5′-UUAAAGGUGGCUGACUAGGTT-3′; SiRNA2: sense 5′-GGAUCAACCACCAAUGGUUTT-3′, antisense 5′-AACCAUUGGUGGUUGAUCCTT-3′; SiRNA3: sense 5′-GCAACAGGGAGAAUUAUUATT-3′, antisense 5′-UAAUAAUUCUCCCUGUUGCTT-3′; the control SiRNA not targeting any annotated human genes: sense 5′-UUCUCCGAACGUGUCACGUTT-3′; antisense 5′-ACGUGACACGUUCGGAGAATT-3′. HCT116/OXA cells were seeded in 6-well plates and transfected with Si-ZEB1 at a final concentration of 50 nM using Lipofectamine 2000 (Life Technologies, Carlsbad, CA) according to the protocol supplied by the manufacturer. The best candidate SiRNA (SiRNA1) was selected following qRT-PCR and Western blot analyses.

Lentivirus infection
--------------------

For the purpose of exploring the role of ZEB1 *in vivo*, a ZEB1-RNAi lentiviral vector (GV112-ZEB1) was constructed by GeneChem (Shanghai, China). Viral titers of Si-ZEB1 and Si-control lentivirus were 1×10^8^ TU/ml. Si-ZEB1 lentivirus was transfected into the HCT116/OXA cells with an optimal infection (MOI) of 30 TU/ml.

Quantitative real-time PCR (qRT-PCR)
------------------------------------

mRNA was isolated from cells using TRIzol reagent (Invitrogen, Waltham, MA). The first strand of cDNA was synthetized from 1 μg of total RNA using PrimeScript™ Kit (TaKaRa, Tokyo, Japan) according to the manufacturer\'s instructions. RT-PCR was performed on a ViiA^TM^7 system (Applied Biosystems, CA) with the All-in-One™ qPCR Mix (Genecopoeia, Guangzhou, China). The primer pairs were synthesized by Sangon Biotech and are as follows: ZEB1, forward 5′-AAGTGGCGGTAGATGGTA-3′ and reverse 5′-TTGTA GCGACTGGATTTT-3′; Snail, forward 5′-CCCCACAGGACTTTGATG-3′ and reverse 5′-AAACAGGAGGCTGAAATAGC-3′; Slug forward 5′-GGGCTCAGTTC GTAAAGG-3 ′and reverse 5′-GAGGAGGTGTCAGATGGA-3′; Twist 5′-TTTACATCCGATTTACTGC-3′ and reverse 5′-CCTAATGCTTTCCCTCAT-3′; E-cadherin forward 5′-CGAGAGCTACACGTTCACGG-3′ and reverse 5′-GGGTGTCGAGGGAAAAATAGG-3′; Vimentin forward 5′-GACGCCATCAACACCGAGTT-3′ and reverse 5′-CTTTGTCGTTGGTTAGCTGGT-3′; MMP2 forward 5′-TACAGGATCATTGGCTACACACC-3′ and reverse 5′-GGTCACATCGCTCCAGACT-3′; MMP9, forward 5′-TGTACCGCTATGGTTACACTCG-3′ and reverse 5′-GGCAGGGACAGTTGCTTCT-3′; GAPDH, forward 5′-GCACCGTCAAGGCTGAGAAC-3′ and reverse 5′-TGGTGAAGACGCCAGTGGA-3′. GAPDH was used as the unified internal control. Relative mRNA expression levels were calculated by the formula 2^-ΔCt^ \[ΔCt = Ct (target gene) - Ct (GAPDH)\].

Western blot
------------

40 μg of the total protein was separated from the cells by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, MA). After being blocked in TBS-T containing 5% skim milk at 37°C for 2 hrs, the membranes were respectively incubated overnight at 4°C with the primary antibodies and were subsequently incubated with the secondary antibodies for 1h at room temperature. The immunoreactive bands were visualized using a ChemiDoc XRS+ system (Bio-Rad, Hercules, CA) and quantitative analysis was performed with Image Lab software (Bio-Rad). GAPDH was used as a loading control.

Immunofluorescence (IF)
-----------------------

IF was performed so as to observe the expression of EMT biomarkers on colon cancer cells. In brief, cells were grown on glass coverslips overnight, then fixed with 4% paraformaldehyde and blocked with 5% normal goat serum. The fixed cells were incubated with the primary antibodies, rabbit anti-E-cadherin (1:200), and mouse anti-Vimentin (1:400) at 4℃ overnight. Subsequently, cells were incubated with Alexa Fluor 546 or Alexa 488-conjugated secondary antibody (1:400, Life Technologies) for 1 h at room temperature. Finally DAPI was added for 3 minutes to stain the nuclei. DM-5000B fluorescence microscopy (Leica) was used for image capture.

Xenograft models
----------------

To investigate the role of ZEB1 on OXA-resistance of colon cancer cells *in vivo,* we used a xenograft animal model (immunodeficient BALB/c nude mice; 4 weeks old, male, 18.0 ± 2.0 g). Si-ZEB1 lentivirus and the negative control lentivirus (Si-NC) were transfected into 5 × 10^6^ HCT116/OXA cells respectively. Those cells were then suspended in 0.15 ml of serum-free culture medium and subcutaneously injected into the right anterior armpit of mice. Starting a week later, mice were subcutaneously injected with OXA (0.8 mg/kg/w) for a period of 4 weeks. Mice received intravenous injections of MMPSense™ 750 FAST fluorescent imaging agent (PerkinElmer, Boston, MA). 6 h later, mice were imaged by Fluorescence Molecular Tomography (FMT-4000, PerkinElmer) to measure MMP activity *in vivo*. All treatment of animals was in strict accordance with the guidelines of the Animal Center of Central South University, and all animal experimental procedures were approved by the Experimental Animal Ethical Committee of Central South University.

Immunohistochemistry (IHC) and the TdT-mediated dUTP-biotin nick end labeling (TUNEL) assays
--------------------------------------------------------------------------------------------

Tumor tissues derived from colon cancer xenograft tumors were fixed in 10% formalin, dehydrated, and embedded in paraffin. 4μm-thick sections were then stained for Ki67 (1:200, CST), E-cadherin (1:200, Abcam), Vimentin (1:400, Abcam), and ZEB1 (1:500, Sigma). The IHC staining was scored according to the percentage of positive-staining cells and staining intensity as previously described [@B18].

TUNEL assay was used to identify ZEB1 involvement in apoptosis of CC cells derived from xenograft tumor tissues using a TUNEL assay kit purchased from Roche Applied Science (Mannheim, Germany). Glass containing tumor tissue was washed with 1×PBS and fixed with 4% paraformaldehyde for 1h. Fixed cells were permeabilized, and then incubated with TdT and DAB-labeled dUTP. Images were captured using a DM-5000B microscopy (Leica).

Statistical Analysis
--------------------

Data is presented as the mean ± SD. Statistical analysis was performed using GraphPad Prism software (Version 5.01, GraphPad Software Inc, San Diego, CA). ZEB1 expression and the clinicopathological characteristics of colon cancer were compared using χ2 test. The cumulative OS and PFS Survival curves were calculated using Kaplan-Meier method and Log-rank test. Cox proportional hazards regression model was established to identify the predictive factors that independently affected the prognosis of colon cancer. Student\'s t-tests were used to compare differences between two groups, unless otherwise specified. All the tests were two-sided and differences were considered to be statistically significant when the *P* value was calculated to be \< 0.05.

Results
=======

ZEB1 overexpressed in tumor tissue was significantly correlated with colon cancer prognosis
-------------------------------------------------------------------------------------------

ZEB1 protein expression was located in nucleus (Figure [1](#F1){ref-type="fig"}A) and associated with lymph node metastasis and the depth of invasion tumors (*p\<*0.05, Table [1](#T1){ref-type="table"}). Based on IHC staining intensity, 33.1% (39/118) and 66.9% (79/118) cases were respectively defined as low and high ZEB1 protein expression in 118 colon cancer specimens (Table [1](#T1){ref-type="table"}). Median PFS in these two groups were 11.6 months (95% CI, 9.34-11.91) and 7.23 months (95% CI, 7.10-9.18) respectively (*p*=0.0222; Figure [1](#F1){ref-type="fig"}B).The median OS tended to be longer in patients with low ZEB1 expression, 14.0 months (95% confidence interval \[CI\], 11.63-14.97), compared with 9.34 months (95% CI, 8.34-11.04) in patients with high ZEB1 expression (*p*=0.0064; Figure [1](#F1){ref-type="fig"}B).

A multivariable Cox proportional hazards model constructed in the independent cohort found that ZEB1 expression was independent prognostic factors for PFS in CC patients (HR=1.542, *p*=0.023) and OS (hazard ratio \[HR\]=1.588, *p*=0.016, Table [2](#T2){ref-type="table"}).

HCT116/OXA cells exhibited different OXA sensitivity and cell morphology relative to HCT116 parent cells
--------------------------------------------------------------------------------------------------------

Relative to HCT116 cells, HCT116/OXA cells exhibited OXA resistance and morphological changes, which included the formation of pseudopodium and the development of a spindle-shaped appearance (Figure [2](#F2){ref-type="fig"}A). The colony formation assay showed that the proliferation capacity of HCT116/OXA cells without OXA treatment was weaker than that in parental cells (*P* \< 0.01, Figure [2](#F2){ref-type="fig"}B). After being treated with OXA at different concentrations for 48 hrs, HCT116/OXA cells exhibited an IC~50~ value of 127.5 μM, while that of HCT116 cells was 16.95 μM (Figure [2](#F2){ref-type="fig"}C). Therefore, the OXA-resistant index of HCT116/OXA was found to be 7.52.

OXA promoted cell apoptosis and suppressed CC cell\' proliferation
------------------------------------------------------------------

HCT116 cells treated with OXA at the IC~50~ concentration of 17 μM exhibited increased expression of cleaved Caspase-3--- a major mediator of cell death--- in contrast with HCT116/OXA cells where expression was significantly down-regulated. The expression of Bcl-2--- a major the mainly anti-apoptosis gene--- was unchanged in HCT116 cells; while Bcl-2 expression was significantly elevated in HCT116/OXA cells (Figure [2](#F2){ref-type="fig"}D). Moreover, apoptosis rate was significantly increased in the case of HCT116 cells relative to that of HCT116/OXA cells (40.38 ± 3.39 *vs.* 19.28 ± 1.20%, *P* \< 0.05, Figure [2](#F2){ref-type="fig"}E).

HCT116/OXA cells exhibited up-regulated ZEB1 and an EMT phenotype
-----------------------------------------------------------------

EMT plays a critical role in drug resistance. qRT-PCR and Western blot analyses indicated that HCT116/OXA cells displayed a greater EMT phenotype compared to HCT116 parent cells and normal colon epithelial cells (NCM460) as evidenced by a relative down-regulation of the epithelial biomarker E-cadherin and up-regulation of the mesenchyme biomarker Vimentin (Figure [3](#F3){ref-type="fig"}A & [3](#F3){ref-type="fig"}B). The EMT phenotype of HCT116/OXA cells was confirmed by IF staining (Figure [3](#F3){ref-type="fig"}C). Consistent with an EMT phenotype, HCT116/OXA cells exhibited increased ECM degradation as evidenced by heightened levels of MMP2 and MMP9 expression (Figure [3](#F3){ref-type="fig"}A & [3](#F3){ref-type="fig"}B). Meanwhile, EMT functional assays such as transwell and scratch wound healing assays revealed that HCT116/OXA cells had a higher capacity for invasion and migration relative to HCT116 cells (Figure [3](#F3){ref-type="fig"}D & [3](#F3){ref-type="fig"}E, *P* \< 0.01, respectively). We also tested the expression of four vital EMT transcription factors Snail, ZEB1, Twist and Slug in HCT116 and HCT116/OXA cells. qRT-PCR and Western blot analyses showed that expression of these four EMT-TFs was increased in HCT116 and HCT116/OXA cells, as compared with NCM460 cells. And the expression of EMT-TFs in HCT116/OXA cells was higher than that in HCT116 cells (Figure [3](#F3){ref-type="fig"}F & [3](#F3){ref-type="fig"}G). Of these four EMT transcriptional factors (EMT-TFs) the expression of ZEB1 was the most elevated (Figure [3](#F3){ref-type="fig"}F & [3](#F3){ref-type="fig"}G), suggesting that ZEB1 may be a particularly important regulator of OXA-sensitivity in CC cells.

ZEB1 silencing increased apoptosis and rescued OXA-sensitivity in HCT116/OXA cells
----------------------------------------------------------------------------------

To explore the role of ZEB1 in CC cell OXA-resistance, we constructed three candidate pairs of ZEB1 SiRNA sequences. SiRNA1 targeting ZEB1 was confirmed as the most effective SiRNA sequence at blocking ZEB1 mRNA and protein expression (Figure [4](#F4){ref-type="fig"}A & [4](#F4){ref-type="fig"}B). The CCK8 assay demonstrated that knockdown of ZEB1 significantly reduced the IC~50~ of OXA in HCT116/OXA cells to 35.90 μM from 125.5 μM in the Si-control groups (Figure [4](#F4){ref-type="fig"}C, *P* \< 0.01). Moreover, the colony formation assay indicated that Si-ZEB1 groups had a lower proliferation capacity than Si-control groups (Figure [4](#F4){ref-type="fig"}D, *P* \< 0.01). In the Si-ZEB1 HCT116/OXA group treated with 36 μM OXA (IC~50~ concentration), ZEB1 silencing resulted in activation of cellular apoptosis pathways, as evidenced by significantly increased Caspase-3 expression and decreased expression of Bcl-2, relative to Si-control cells (Figure [4](#F4){ref-type="fig"}E). Flow cytometry results showed that ZEB1 depletion promoted CC cell apoptosis (Si-ZEB1 *vs.* Si-control: 35.21 ± 2.47% *vs.* 26.37 ± 4.18%, *P \<* 0.05, Figure [4](#F4){ref-type="fig"}F). These results demonstrate that blocking ZEB1 expression effectively attenuated OXA-resistance in HCT116/OXA cells.

Knockdown of ZEB1 reversed the EMT phenotype in HCT116/OXA cells
----------------------------------------------------------------

To further investigate the role(s) of ZEB1 in OXA-resistance in HCT116/OXA cells with an EMT phenotype, we measured mRNA and protein expression of E-cadherin, Vimentin, MMP2, and MMP9. The expression of E-cadherin was increased but that of Vimentin, MMP2, MMP9 were decreased in the Si-ZEB1 group, as compared to in the Si-control group (Figure [5](#F5){ref-type="fig"}A & [5](#F5){ref-type="fig"}B). Moreover, IF staining against EMT biomarkers revealed an attenuation of EMT phenotype induced by ZEB1 knockdown in HCT116/OXA cells (Figure [5](#F5){ref-type="fig"}C). Transwell and scratch wound healing assays showed that the migration and invasion capacities of CC cells were reduced in the Si-ZEB1 group relative to the Si-control group (Figure [5](#F5){ref-type="fig"}D & [5](#F5){ref-type="fig"}E, *P* \< 0.01, respectively). Taken together, the data shows that ZEB1 is an important factor in EMT and OXA-resistance in CC cells.

Knockdown of ZEB1 rescued OXA-sensitivity in a subcutaneous xenograft nude mice model
-------------------------------------------------------------------------------------

Figure [6](#F6){ref-type="fig"}A shows that HCT116/OXA cell-derived tumor tissues located at the implantation sites were smaller in the Si-ZEB1 group than those from the Si-control group after four weeks of OXA treatment (Si-ZEB1 *vs. S*i-control: 0.35± 0.21 cm^3^ *vs.* 1.15± 0.18 cm^3^, *P* \< 0.001). We measured activity of MMP in subcutaneous tumors using a fluorescent imaging system six weeks following tumor implantation. Figure [6](#F6){ref-type="fig"}B shows that mean MMP activity indicated by fluorescence intensity was decreased when ZEB1 expression was depleted (Si-control *vs.* Si-ZEB1: 119.8 ± 19.30 *vs.* 66.14± 14.81, *P* \< 0.05). Using qRT-PCR and IHC staining to measure the expression of EMT biomarkers, we found that ZEB1 knockdown reversed the EMT phenotype as evidenced by the up-regulation of E-cadherin and down-regulation of Vimentin (Figure [6](#F6){ref-type="fig"}C & [6](#F6){ref-type="fig"}D). TUNEL assay showed that the apoptosis rate of CC cells in Si-ZEB1 group was higher than that in the Si-control group (48.52 ± 5.39% *vs.* 33.97 ± 3.52%, *P* \< 0.05, Figure [6](#F6){ref-type="fig"}D). IHC results revealed a higher cell proliferation index (Ki-67) in Si-ZEB1 groups relative to control (56.47 ± 1.98% *vs.* 28.61 ± 6.28%, *P* \< 0.01, Figure [6](#F6){ref-type="fig"}D). In short, ZEB1 silencing significantly reversed the EMT phenotype and attenuated OXA-resistance in HCT116/OXA cells*in vivo*.

Discussion
==========

Aberrant activation of ZEB1 had been shown to regulate cancer cell differentiation, migration, invasion, proliferation, apoptosis and chemo-resistance in the progression of various cancers [@B19]-[@B21]. An analysis of 92 patients with primary colorectal cancer (CRC) indicated that overexpression of ZEB1 might be an independent prognostic factor for patients with CRC [@B22]. Here we demonstrated that ZEB1 expression was significantly elevated in colon cancer tissues of advanced stage IV receiving OXA-based chemotherapy, and also in OXA-resistant CC cells as compared with their parental cells.

Our results indicate that EMT is importantly involved in OXA-resistance and that ZEB1 plays a critical role in the EMT-regulated OXA sensitivity of CC cells. After receiving OXA treatment, HCT116 cells without an EMT phenotype exhibited up-regulated Caspase-3 but an unchanged expression of anti-apoptosis protein of Bcl-2; in contrast to HCT116/OXA cells with an EMT phenotype, which showed the opposite. Probably, the enhanced anti-apoptosis characteristics of in HCT116/OXA cells may contribute to the EMT phenotype [@B23], [@B24]. It has been reported that cell proliferation is enhanced after the development of EMT characteristics in human melanoma [@B25]. However, we found that the proliferation capacity of OXA-resistance cells (HCT116/OXA) was weaker than that of the parental cells (HCT116). It may be a unique mechanism which is responsible for OXA-resistance in CC cells Moreover, knockdown of ZEB1 in HCT116/OXA cells resulted in a reversal of EMT and an enhancement of OXA-sensitivity *in vitro* and *in vivo*. Consistent with our findings, Yoshihiro showed that ZEB1 knockdown activates the apoptosis pathway in non-small cell lung cancer (NSCLC) cell lines and lung tumors [@B26]. Also, ZEB1 depletion may enhance the sensitivity of melanoma cells to mitogen-activated protein kinase (MAPK) inhibitors *via* reversing EMT reversal [@B20].

Chemo-resistance is frequently accompanied by metastasis [@B27]. Previous studies have shown that acquisition of an EMT phenotype in CRC cells increases migration and invasion abilities [@B28]. Our data indicated that OXA-resistance CC cells with an EMT phenotype exhibited had a significantly greater metastasis ability, which could be reversed by ZEB1 silencing. Taken together, our findings suggest that ZEB1 overexpression would augment OXA resistance in CC cells by triggering EMT along with development of anti-apoptosis, invasion and migration characteristics. These processes are reflected at the molecular level by the activation of anti-apoptosis pathways involving Bcl-2 overexpression and by ECM degradation involving up-regulation of MMP2 and MMP9 expression.

The present study found that ZEB1 to be overexpressed in OXA-resistant CC cells, as compared with their parent cells. The mechanisms of ZEB1 activation in malignant tumors are complex. Some studies have suggested that TGF-β/SMADs and Wnt/β-catenin signaling pathways directly influence the nuclei expression of ZEB1. TGF-β expression is high in the tumor micro-environment and associated with neoplasm angiogenesis, invasion, migration, proliferation and stemness [@B29]-[@B31]. A recent research revealed that using TGF-β treated glioblastoma (U87 cells) induced a positive expression of SMAD2 and ZEB1, but an absence of epithelial markers [@B32]. TGF-β signaling results in trimeric SMAD complex (SMAD2-SMAD3-SMAD4) formation *via* two types of tetrameric complex (TβRI and TβRII); the trimeric SMAD complex translocates to the nucleus where it ZEB1 expression is activated [@B33]. Wnt/β-catenin signaling participates in EMT by triggering ZEB1 expression [@B34], [@B35]. The activated Wnt protein inhibits phosphorylation of β-catenin through regulation of APC-axin-GSK-3β compound; un-phosphorylated β-catenin translocates to the nucleus and induces activation of ZEB1 expression [@B36].

In summary, ZEB1 promotes EMT and plays an important role in the OXA-resistance of colon cancer cells. Exploring ZEB1\'s biological role may reveal a strategy for using ZEB1 as a prognostic biomarker of drug-resistance in tumors and/or a potential target gene for therapy.
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![**ZEB1 expression served as a poor prognosis for colon cancer.** (A) HE and IHC staining of ZEB1 protein expression in colon cancer tissues and adjacent non-tumorous tissue (Original magnification: ×200). (B) Survival curves, which were evaluated by the log-rank test, indicated PFS and OS of colon cancer patients with high or low ZEB1 expression in the independent cohort (n=118).](jcav08p3555g001){#F1}

![**Proliferation and apoptosis of HCT116 and HCT116/OXA cells.** (A) Morphological changes of HCT116/OXA cells: spindle-shape appearance and pseudopodium formation (Original magnification: × 400). (B) Proliferation abilities of HCT116 and HCT116/OXA cells tested by colony formation assays (*P* \< 0.01). (C) CCK8 assay was carried out to identify IC~50~ values of HCT116 and HCT116/OXA cells to OXA. The drug index was calculated as: IC~50~ of OXA-resistant cells / IC~50~ of the parental cells. (D) The cells were treated with or without 17μM OXA for 48 hrs, the expression of apoptotic protein caspase-3, and anti-apoptotic protein Bcl-2 in HCT116 and HCT116/OXA cells evaluated by Western blot was normalized to the expression of GAPDH. (E) Apoptosis rates of colon cancer cells treated with or without OXA at 17 μM for 48 hrs were detected by flow cytometry with Annexin V / PI staining. All experiments were repeated in triplicate and the data were shown as mean ± SD. ^\*^: *P* \< 0.05, ^\*\*^: *P* \< 0.01.](jcav08p3555g002){#F2}

![**OXA-resistant cells (HCT116/OXA) exhibited up-regulated ZEB1 and an EMT phenotype.** (A & B) Expression of epithelial biomarker (E-cadherin), mesenchymal biomarker (Vimentin) and matrix metalloproteinases (MMP2, MMP9) were measured by qRT-PCR and Western blot analyses. (C) Representative double immunofluorescence staining of the expression and co-localization of EMT biomarkers E-cadherin / Vimentin (Original magnification: ×400). (D) Transwell assays were used to determine the invasion capacity of HCT116/OXA and HCT116/OXA cells. Cells were starved for 12 hrs before being seeded into the matrigel chamber. (E) Scratch wound healing assays were used to test the migratory abilities of OXA-resistant cells and their parent colon cancer cells. (F & G) mRNA and protein expression of four EMT transcriptional factors (EMT-TFs): Snail, Slug, ZEB1 and Twist in normal colon epithelial cell and colon cancer cells. Compared to NCM460 group, ^\#^: *P* \< 0.05, ^\#\#^: *P* \< 0.01, ^\#\#\#^: *P* \< 0.001. Compared to HCT116 group, ^\*^: *P* \< 0.05, ^\*\*^: *P* \< 0.01, ^\*\*\*^: *P* \< 0.001.](jcav08p3555g003){#F3}

![**ZEB1 silencing promoted apoptosis and restored OXA-sensitivity of HCT116/OXA cells.** (A & B) SiRNA1 candidate sequence pairs with the highest inhibition efficiency of ZEB1 expression confirmed by qRT-PCR and Western blot analyses were selected for subsequent experiments. The differences in ZEB1 expression levels among different groups were tested by one-way ANOVA analysis. (C) CCK8 assays were performed to identify the role(s) of ZEB1 in the OXA-sensitivity of colon cancer cells. (D) ZEB1 knockdown inhibited proliferation of HCT116/OXA cells, as measured by colony formation assays (*P* \< 0.01). (E) The expression of apoptotic protein Caspase-3 and anti-apoptotic protein Bcl-2 measured by Western blot was normalized to GAPDH protein expression. (F) ZEB1 knockdown significantly enhanced OXA-induced apoptosis in HCT116/OXA cells (*P* \< 0.05). All data represented as mean ± SD were from three independent experiments.^\*^: *P* \< 0.05, ^\*\*^: *P* \< 0.01, ^\*\*\*^: *P* \< 0.001.](jcav08p3555g004){#F4}

![**Si-ZEB1 reversed the EMT phenotype of HCT116/OXA cells**. (A & B) mRNA and protein expression of EMT biomarkers in HCT116/OXA cells following ZEB1 silencing. (C) Expression of EMT biomarkers E-cadherin / Vimentin evaluated by IF staining (Original magnification: ×400). (D) Transwell assays revealed dramatically increased invasion ability of HCT116/OXA cells in the Si-ZEB1 group, compared with that in Si-control group (*P* \< 0.01). (E) Scratch wound healing assays indicated that Si-ZEB1 inhibited the migration of OXA-resistant colon cancer cells (*P* \< 0.01). ^\*^: *P* \< 0.05, ^\*\*^: *P* \< 0.01,^\*\*\*^: *P* \< 0.001.](jcav08p3555g005){#F5}

![**ZEB1 knockdown attenuated OXA-resistance of colon cancer cells *in vivo***. (A) Tumor size was measured by the formula: V (cm^3^) = (L × W^2^) × 0.5 (L: Tumor length, W: Width). (B) Mean fluorescence intensity of tumors was equal to the total MMP Fluorescence Signal / Tumor Size, which was calculated by the TrueQuant™ (the Quantitative Tomography *in vivo* Imaging Software, PerkinElmer) and used to reflect mean MMP activitiy *in vivo*. (C) mRNA expression of EMT-related biomarkers in Xenograft tumors was analyzed by qRT-PCR. (D) HE and IHC analysis showed that the expression of Ki67 and Vimentin were down-regulated, while expression of E-cadherin was up-regulated in the Si-ZEB1 group, as compared with that in the Si-control group (Original magnification: × 200). TUNEL assay indicated that the apoptosis rate was increased in HCT116/OXA cells following ZEB1 silencing (Original magnification: × 200). Data were shown as mean ± SD. ^\*^: *P* \< 0.05, ^\*\*^: *P* \< 0.01,^\*\*\*^: *P* \< 0.001.](jcav08p3555g006){#F6}

###### 

The relationship between the ZEB1 protein expression and clinicopathological features in colon cancer

  -------------------------------------------------------------------------------------
  Clinicopathological features   n          ZEB1 expression (118)               
  ------------------------------ ---------- ----------------------- ----- ----- -------
  Age (years)                    ≤60        58                      38    20    0.448

                                 \>60       60                      41    19    

  Sex                            Male       62                      42    20    0.501

                                 Female     56                      37    19    

  Tumor size (mm)                ≤50        72                      47    25    0.391

                                 \>50       46                      32    14    

  Location                       Proximal   57                      35    22    0.149

  Distal                         61         44                      17          

  Depth of invasion              T1-2       86                      55    31    0.013

  T3-4                           32         24                      8           

  Differentiation                Well-Mod   85                      53    32    0.066

                                 Poor       33                      26    7     

  Lymph node metastasis          N0\        42\                     23\   19\   0.030
                                 N1-N2      76                      56    20    

  CEA (μg/μL)                    ≤5         79                      53    26    0.561

                                 \>5        39                      26    13    
  -------------------------------------------------------------------------------------

###### 

Multivariate Analysis by a Cox Proportional Hazards Regression Model in Colon Cancer

  Clinicopathological variables         PFS                   OS                              
  ------------------------------------- --------------------- ---------- -------------------- ----------
  Age (≤60 vs. \>60)                    0.0368(0.017-0.942)   0.266      0.034(0.013-0.847)   0.143
  Sex (Male vs. Female)                 0.275(0.033-2.288)    0.232      0.229(0.033-2.266)   0.229
  Tumor size (mm) (≤60 vs. \>60)        0.617(0.200-1.905)    0.493      0.415(0.203-1.933)   0.415
  Location (Proximal vs. Distal)        1.220(0.772-1.927)    0.395      1.232(0.780-1.946)   0.362
  Depth of invasion (T1-2 vs. T3-4)     0.952(0.449-2.020)    0.899      0.929(0.436-1.979)   0.849
  Differentiation (Well-Mod vs. Poor)   1.072(0.289-3.980)    0.917      0.992(0.269-3.659)   0.532
  Lymph node metastasis (N0 vs. N1-2)   0.264(0.130-0.536)    \<0.0001   0.299(0.143-0.628)   \<0.0001
  CEA (μg / μL) (≤5 vs. \>5)            1.354(0.304-6.028)    0.691      1.377(0.310-6.113)   0.674
  ZEB1 expression (Low vs. High)        1.542(0.839-2.832)    0.023      1.588(0.953-2.646)   0.016
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